clinicaltrials.gov/ct2/show...
After several false starts, we're driving to Houston next week for the pre-trial screening blood tests, CT, and bone marrow biopsy. I think Dr. Thompson was a bit too optimistic before he left MDA, thinking it would happen in November 2022 or January.
I finally got a copy of the actual protocol document, and made contact with the Study Coordinator to nail down dates. At this point they have a couple dozen of the planned 60 participants. Since this is only happening at MDA, I expect it will draw patients mostly from Texas.
We will be commuting each week from New Orleans, Louisiana, and hope to get some financial help with hotels and insurance costs. I will be applying to the Leukemia Lymphoma Society for co-pay assistance as soon as I'm accepted, as well as asking MDA to ask my insurance company for an Out of Network Exception. LOXO/Lilly is paying for the Pirtobrutinib, but I haven't seen in writing who pays for anything else.
I have the impression that once the trial gets going, there will be fewer problems for new participants as well as for my own participation.
The protocol is not identical to the NCI document that was published on cancer.gov that I posted earlier. I suspect that was an early draft and may be updated soon.
The actual protocol still has 2 arms - 1 for treatment naive, and 1 for Richters Transformation patients.
It calls for:
28 day cycles (this is standard, I believe)
Clinic visits every week for the first 2 cycles, and then every other week for the remaining cycles.
7 cycles of pirtobrutinib
6 cycles of Obinutuzumab, 1 infusion per month, with 4 infusions the first cycle (day 1, 2, 8, & 15) . The first infusion is the partial dose, and the remainder on day 2. I think that's fairly standard. But I get the impression that by not doing a day 22 infusion, and not repeated the weekly in cycle 2 means this is less aggressive than standard V&O.
6 cycles of Venetoclax starting , cycles 2-7, with a 5 week ramp-up
Allopurinol to combat TLS kidney effects during the first 2 cycles
Valaciclovir to try to prevent latent virus reactivation (VZV/shingles, HSV-1, HSV-2, and possibly others).
After 7 cycles for treatment naive, a final bone marrow biopsy. Bone marrow biopsy after the 1st, 4th and 7th cycles for Richters arm.
If no response after 7 cycles, an additional 6 cycles of Pirtobrutinib and Venetoclax will be given. The protocol document does not mention MRD testing. They do not define "response"in the protocol document like they do on the clinicaltrials link above. I will be asking about that.
Follow-up for 5 years for treatment naive, roughly every 3 months for 2 years and then every 6 months.
If you're interested:
Leukemia Clinic Main Number: 713-792-8760
Email: leukemia@mdanderson.org
=seymour=